Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus
The 34th annual PM Society Awards, announced on 24th January, saw Havas Lynx Group take an impressive seven Gold awards across work for six different clients and VCCP six Gold awards with two ph
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.